

SUPPLEMENTAL MATERIAL

Immediate and delayed procedural stroke or death in stenting versus endarterectomy for symptomatic carotid stenosis

Mandy D Müller MD¹, Stefanie von Felten PhD², Ale Algra MD³, Jean-Pierre Becquemin MD⁴, Martin Brown MD⁵, Richard Bulbulia MD⁶, David Calvet MD⁷, Hans-Henning Eckstein MD⁸, Gustav Fraedrich MD⁹, Alison Halliday MD¹⁰, Jeroen Hendrikse MD¹¹, John Gregson PhD¹², George Howard DrPh¹³, Olav Jansen MD¹⁴, *Jean-Louis Mas MD⁷, *Thomas G Brott MD¹⁵, *Peter A Ringleb MD¹⁶, *Leo H Bonati MD^{1,5}; for the Carotid Stenosis Trialists' Collaboration. **contributed equally*

1. Department of Neurology and Stroke Center, University Hospital Basel, Basel, Switzerland
2. University of Basel, Department of Clinical Research, Clinical Trial Unit, c/o University Hospital Basel, Basel, Switzerland
3. Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus and Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
4. Vascular Institute Paris East, Hôpital privé Paul D'Egine, Ramsay group, Champigny sur Marne, France
5. Department of Brain Repair and Rehabilitation, UCL Institute of Neurology, University College London, London, UK

6. MRC Population Health Research Unit, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, Oxford University, Oxford, UK
7. Department of Neurology, Hôpital Sainte-Anne, Université Paris-Descartes, DHU Neurovasc Sorbonne Paris Cité, INSERM U894, Paris, France.
8. Department of Vascular and Endovascular Surgery, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
9. Department of Vascular Surgery, Medical University of Innsbruck, Innsbruck, Austria
10. Nuffield Department of Surgical Sciences, John Radcliffe Hospital, Oxford, UK
11. Department of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands
12. Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom
13. Department of Biostatistics, UAB School of Public Health, Birmingham, USA
14. Clinic for Radiology and Neuroradiology, UKSH Campus Kiel, Kiel, Germany
15. Department of Neurology, Mayo Clinic, Jacksonville, USA
16. Department of Neurology, University of Heidelberg Medical School, Heidelberg, Germany

Acknowledgments and Funding

The prospective individual patient-data meta-analysis by the **Carotid Stenosis Trialists' Collaboration** was funded by a grant from The Stroke Association. The Endarterectomy versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis trial was funded by a grant from the Programme Hospitalier de Recherche Clinique of the French Ministry of Health, Assistance Publique–Hôpitaux de Paris. The Stent-Protected Angioplasty versus Carotid Endarterectomy in symptomatic patients trial was funded by grants from the Federal Ministry of Education and Research, Germany, the German Research Foundation, the German Society of Neurology, the German Society of Neuroradiology (German Radiological Society), Boston Scientific, Guidant, and Sanofi-Aventis. The International Carotid Stenting Study was funded by grants from the Medical Research Council, the Stroke Association, Sanofi-Synthélabo, and the European Union. The Carotid Revascularization Endarterectomy vs. Stenting Trial was supported by the National Institute of Neurological Disorders and Stroke (NINDS) and the NIH (R01 NS 038384) and received supplemental funding from Abbott Vascular Solutions (formerly Guidant), including donations of Accunet and Acculink systems, equivalent to approximately 15% of the total study cost, to CREST centers in Canada and to CREST centers in the United States that were at Veterans Affairs sites.

Involvement of the authors in the CSTC steering committee is as follows: A. Algra (independent chair); EVA-3S: J.P. Becquemin, D. Calvet, J-L. Mas; ICSS: L.H. Bonati (coordinator), M.M. Brown, J. Hendrikse; SPACE and SPACE-2: H-H. Eckstein, G. Fraedrich, O. Jansen, P.A. Ringleb; CREST and CREST-2: T.G. Brott, G. Howard, G.S. Roubin; ACST-1 and ACST-2: R. Bulbulia, A. Halliday; trial statistician: J. Gregson. The members of the Steering Committees and a list of Investigators contributing data to the trials including those in this pooled analysis can be found in earlier publications.

Supplemental tables

Table I. *Stent design and protection devices*

	Total (n=1,557)	EVA-3S (n=246)	SPACE (n=573)	ICSS (n=738)
Stent design (n, %)				
Open-cell	595 (38.2)	101 (41.1)	127 (22.2)	367 (49.7)
Precise RX (Cordis)	263 (16.9)	26 (10.6)	35 (6.1)	202 (27.4)
Acculink (Guidant/Abbott)	232 (14.9)	70 (28.5)	92 (16.1)	70 (9.5)
Protégé (EV3)	82 (5.3)	0 (0.0)	0 (0.0)	82 (11.1)
Next Stent (Boston Scientific)	3 (0.2)	0 (0.0)	0 (0.0)	3 (0.4)
Exponent (Medtronic)	3 (0.2)	0 (0.0)	0 (0.0)	3 (0.4)
Zilver (Cook Medical)	5 (0.3)	5 (2.0)	0 (0.0)	0 (0.0)
S.M.A.R.T. (Cordis)	7 (0.4)	0 (0.0)	0 (0.0)	7 (0.9)
Closed-cell	962 (61.8)	145 (58.9)	446 (77.8)	371 (50.3)
Carotid Wallstent (Boston Scientific)	899 (57.7)	145 (58.9)	436 (76.1)	318 (43.1)
Xact (Abbott)	58 (3.7)	0 (0.0)	10 (1.7)	48 (6.5)
Cristallo ideale (Invatec/Medtronic)	5 (0.3)	0 (0.0)	0 (0.0)	5 (0.7)
Protection device used (n, %)	950 (61.0)	227 (92.3)	153 (26.7)	570 (77.2)
Distal filters*	827 (87.1)	160 (70.5)	133 (86.9)	534 (93.7)
AccUNET (Guidant)	15 (1.6)	5 (2.2)	4 (2.6)	6 (1.1)
Angioguard (Cordis)	124 (13.1)	21 (9.3)	16 (10.5)	87 (15.3)
Emboshield (Abbott)	131 (13.8)	24 (10.6)	18 (11.8)	89 (15.6)
Filterwire (Boston Scientific)	374 (39.4)	61 (26.9)	66 (43.1)	247 (43.3)
Interceptor (Medtronic)	1 (0.1)	0 (0.0)	0 (0.0)	1 (0.2)
Mednova Neuroshield (Abbott)	29 (3.1)	0 (0.0)	5 (3.3)	24 (4.2)
Spider (EV3)	153 (16.1)	49 (21.6)	24 (15.7)	80 (14.0)
Distal occlusion*	86 (9.1)	67 (29.5)	16 (10.5)	3 (0.5)
Percusurge (Medtronic)	86 (9.1)	67 (29.5)	16 (10.5)	3 (0.5)
Flow reversal*	34 (3.6)	0 (0.0)	4 (2.6)	30 (5.3)
Neuroprotection System (GORE)	22 (2.3)	0 (0.0)	0 (0.0)	22 (3.9)
Mo.Ma (Invatec)	5 (0.5)	0 (0.0)	4 (2.6)	1 (0.2)
Parodi AES (Arteria)	7 (0.7)	0 (0.0)	0 (0.0)	7 (1.2)
Type of device unknown*	0	0	0	3 (0.5)

*Patients with deployed stents and available data on stent type and protection device use are included. Data are n/N (%), unless otherwise indicated. *Percentages of all protection devices.*